853748-69-3

Upstream product

• 58-61-7 adenosine 
• 853748-67-1 Diisopropyl-phosphoramidous acid (2R,3R,4R,5R)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(6-isobutyrylamino-purin-9-yl)-4-[2-(2,2,2-trifluoro-acetylamino)-ethoxy]-tetrahydro-furan-3-yl ester 2-cyano-ethyl ester 
• 853748-66-0 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-(trifluoroacetamido)ethyl)-N⁶-isobutyryladenosine 
• 853748-64-8 3',5'-bis-O-(tert-butyldimethylsilyl)-2'-O-(2-(trifluoroacetamido)ethyl)-N⁶-isobutyryladenosine 
• 853748-62-6 3',5'-bis-O-(tert-butyldimethylsilyl)-2'-O-(2-methanesulfonylethyl)-N⁶-isobutyryladenosine 
• 853748-63-7 3',5'-bis-O-(tert-butyldimethylsilyl)-2'-O-(2-azidoethyl)-N⁶-isobutyryladenosine 
• 853748-61-5 3',5'-bis-O-(tert-butyldimethylsilyl)-2'-O-(2-hydroxyethyl)-N⁶-isobutyryladenosine 
• 853748-59-1 methyl 2-(((2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-3-yl)oxy)acetate 
• 853748-60-4 2-(((2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-3-yl)oxy)ethanol 
• 853748-65-9 2'-O-(2-(trifluoroacetamido)ethyl)-N⁶-isobutyryladenosine 
• 304442-35-1 methyl 2-(((2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)acetate 
• 853748-68-2 3',5'-bis-O-(tert-butyldimethylsilyl)-2'-O-(2-(triphenylmethylthio)ethyl)-N⁶-isobutyryladenosine 

Downstream Products

• 853748-70-6 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-(triphenylmethylthio)ethyl)-N⁶-isobutyryladenosine 

Relevant academic research and scientific papers

ANTISENSE OLIGONUCLEOTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES

The invention relates to an antisense or siRNA oligonucleotide or conjugate with improved pharmacokinetic properties, methods of producing the same as well as the use of such compounds and conjugates, e.g. as pharmaceutical composition, a pharmaceutical kit, a medicament or a tool in biomedical research. The conjugates of the invention have the formula I being P - (L - S - S - Y - X)n, wherein P represents a natural, artificial and/or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence; S represents sulfur; X represents a ligand; Y represents a spacer and n is an integer ranging from 1 to the oligonucleotide length of P. The oligonucleotides of the invention have the formula II being P- (L - S - R)n, wherein P represents a natural, artificial and /or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence, S represents sulfur, R represents either hydrogen or a thiol protecting group, preferably trityl or tertiary butyl, and n is an integer ranging from 1 to the oligonucleotide length of P. In addition, the pharmaceutical composition or pharmaceutical kit or conjugate can be used for the treatment of a disease or disorder that can be at least in part alleviated by therapy, wherein the disease or disorder is selected from the group consisting of bacterial infections, viral infections, cancer, metabolic diseases and immunological disorders and preferably cancer.

Antisense oligonucleotides with improved pharmacokinetic properties

The invention relates to an antisense or siRNA oligonucleotide or conjugate with improved pharmacokinetic properties, methods of producing the same as well as the use of such compounds and conjugates, e.g. as pharmaceutical composition, a pharmaceutical kit, a medicament or a tool in biomedical research. The conjugates of the invention have the formula I being P - (L - S - S - Y - X)n, wherein P represents a natural, artificial and/or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence; S represents sulfur; X represents a ligand; Y represents a spacer and n is an integer ranging from 1 to the oligonucleotide length of P. The oligonucleotides of the invention have the formula II being P- (L - S - R)n, wherein P represents a natural, artificial and /or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence, S represents sulfur, R represents either hydrogen or a thiol protecting group, preferably trityl or tertiary butyl, and n is an integer ranging from 1 to the oligonucleotide length of P. In addition, the pharmaceutical composition or pharmaceutical kit or conjugate can be used for the treatment of a disease or disorder that can be at least in part alleviated by therapy, wherein the disease or disorder is selected from the group consisting of bacterial infections, viral infections, cancer, metabolic diseases and immunological disorders and preferably cancer.

Synthesis of amine- and thiol-modified nucleoside phosphoramidites for site-specific introduction of biophysical probes into RNA

For studies of RNA structure, folding, and catalysis, site-specific modifications are typically introduced by solid-phase synthesis of RNA oligonucleotides using nucleoside phosphoramidites. Here, we report the preparation of two complete series of RNA nu